Published in TB and Outbreaks Week, June 29th, 1998
Researchers found that the technology can be used to identify subtle changes in transcriptional expression of genes in cells of tissues or blood samples obtained during recombinant human interleukin or other immunomodulatory adjunctive therapy.
"Our studies have identified a number of novel candidate genes whose expression can now be studied in detail in order to evaluate their role in the antituberculous response which is enhanced by the administration of recombinant human interleukin 2 (rhuIl-2)," Barbara J. Johnson and colleagues...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.